Precision Medicine Group

What Precision Medicine Group does

Precision Medicine Group is a privately held, vertically integrated drug development and commercialization services provider headquartered at 2 Bethesda Metro Center, Bethesda, Maryland. Founded in 2012 by Mark Clein and Ethan Leder, the company has grown to a global team of approximately 3,500 professionals and operates as a holding company over two principal business units: Precision for Medicine, a biomarker-driven contract research organization offering global clinical trial management, specialty and central lab services, biospecimen procurement, kitting and sample tracking, and a Precision Medicine Intelligence analytics layer; and Precision AQ, a commercialization services group spanning commercial consulting, health economics and outcomes research (HEOR), market access marketing, medical communications, branding and PR, investor relations, and product solutions. Adjacent and wholly-owned operating subsidiaries include QuartzBio (data management and analytics), Project Farma and Precision ADVANCE (cell and gene therapy manufacturing and commercial readiness), and PRECISIONadvisors, PRECISIONeffect, PRECISIONheor, PRECISIONscientia, PRECISIONvalue, Stern Investor Relations, and Precision Biospecimen Solutions.

The company generates revenue primarily through project-based professional services contracts with pharmaceutical, biotechnology, and broader life sciences clients, pricing of which is not publicly disclosed. Customer segmentation is horizontal across pharma, biotech, and life sciences organizations, with deep specialization in advanced modalities including oncology, cell therapy, gene therapy, and rare diseases. Geographic reach spans more than 50 countries, anchored in North America and expanded via a Japan office opened in May 2025 as part of Asia-Pacific growth. The technology stack integrates biomarker-driven trial design, translational informatics, and laboratory operations, augmented by AI-augmented predictive analytics for trial planning and recent technology partnerships with PathAI (AI pathology) and SOPHiA GENETICS (liquid biopsy / DDM Platform).

The company has executed three disclosed acquisitions (Epiontis in 2017, Stern Investor Relations in 2018, and Project Farma in 2021) and raised at least $310M of disclosed funding, including a $275M round in December 2017 led by Berkshire Partners and TPG Growth alongside J.H. Whitney and Oak Investment Partners, plus a $35.16M round in March 2021. Leadership transitioned in October 2024 with Margaret Keegan becoming CEO and the subsequent appointment of Karl Deonanan as CFO, Eric Hodgins as CITO, Tracey Leahy as CPO, and Sofia Baig as President of Precision for Medicine, accompanied by a reported 2026 process in which Blackstone was testing the buyout market for the CRO and commercialization divisions.

Name

Precision Medicine Group

Legal name

Precision Medicine Group, LLC

Website

https://precisionmedicinegrp.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Precision Medicine Group is a private, integrated drug development and commercialization services provider serving pharmaceutical, biotechnology, and life sciences clients globally through Precision for Medicine (biomarker-driven CRO, central lab, biospecimens) and Precision AQ (HEOR, market access, medical communications).

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development and Commercialization Services

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Medical Affairs Scientific Communications (MSL Support/Scientific Response) (HLAGALAF)

Keywords

• Clinical research services
• Biomarker-driven drug development
• Pharmaceutical commercialization services
• Clinical trial management
• Life sciences consulting

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Development Services: CRO services including global clinical trial management, biomarker-driven research, specialty labs, central lab services, and biospecimen services. Revenue generated through project-based contracts with pharmaceutical and life sciences companies.
2. Commercialization Services: Services including commercial consulting, HEOR, market access marketing, medical communications, branding and PR, and investor relations. Supporting life science organizations from launch through product maturity.
3. Precision AQ Services: Commercialization services including product solutions, market access, and external communications for life science clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Precision Medicine Group delivers integrated drug development and commercialization services to pharmaceutical and life sciences clients through two operating groups. Precision for Medicine provides biomarker-driven global CRO services, specialty labs, central lab services, biospecimens, kitting and sample tracking, and precision medicine intelligence. Precision AQ offers commercialization services including commercial consulting, HEOR, market access marketing, medical communications, branding and PR, investor relations, and product solutions.

Product overview

Precision Medicine Group operates as an integrated team of experts offering next-generation drug development and commercialization services. The company is structured around two primary divisions: Precision for Medicine (the premier provider of biomarker-driven research and development) and Precision AQ (the foremost provider of commercialization services). Precision for Medicine offers global CRO services, specialty labs, central lab services, biospecimens, kitting and sample tracking, and precision medicine intelligence. Precision AQ provides commercial consulting, HEOR, market access marketing, medical communications, marketing/branding/PR, investor relations, and product solutions. Additional service lines include QuartzBio for data management, Drug Safety & Pharmacovigilance, and Global Clinical Research Organization services spanning more than 50 countries with expertise in oncology and gene therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision for Medicine Premier provider of biomarker-driven research and development services for pharmaceutical and life sciences clients, offering global CRO services, specialty labs, central lab services, biospecimens, kitting and sample tracking, and precision medicine intelligence to accelerate clinical development.
• Precision AQ Foremost provider of commercialization services supporting life science organizations from launch through product maturity, offering commercial consulting, HEOR, market access marketing, medical communications, marketing/branding/PR, investor relations, and product solutions.
• Global Clinical Trial Services Clinical trial services operating across more than 50 countries, combining international reach with local insight to support research and regulatory compliance, encompassing full-study management, development strategies, and specialized support in oncology and gene therapy.
• Drug Safety & Pharmacovigilance Comprehensive drug safety and pharmacovigilance services to ensure compliance with regulatory requirements and monitor the safety of pharmaceutical products throughout their lifecycle.
• Full-Service Global Clinical Research Organization (CRO) Full-service clinical research organization providing integrated research capabilities to support drug development from early phase through commercialization across global markets.
• Precision Medicine Intelligence Advanced analytics and intelligence services leveraging precision medicine data to inform clinical development decisions and optimize therapeutic strategies.
• QuartzBio Data management and analytics platform supporting integrated data solutions for clinical research, providing centralized biomarker and clinical data management.
• Kitting and Sample Tracking Specialized services for managing and tracking biological samples throughout clinical trials, ensuring sample integrity and chain of custody.
• Specialty Labs Advanced laboratory services supporting biomarker analysis, genomic testing, and specialized diagnostic capabilities for clinical development.
• Central Lab Services Centralized laboratory services providing standardized testing and analysis across global clinical trial sites.
• Biospecimens Procurement, management, and analysis of biological specimens for clinical research and biomarker development.
• Commercial Consulting Strategic consulting services for commercial strategy, market entry, and product launch support for life science organizations.
• HEOR (Health Economics and Outcomes Research) Health economics and outcomes research services to demonstrate the value of pharmaceutical products to payers and health technology assessment bodies.
• Market Access Marketing Services focused on achieving optimal market access and reimbursement for pharmaceutical products.
• Medical Communications Medical communications services including medical writing, publications, and scientific exchange programs.
• Marketing, Branding & PR Marketing, branding, and public relations services to support product positioning and corporate communications.
• Investor Relations & External Communications Investor relations and external communications services for corporate visibility and stakeholder engagement.
• Institute@Precision Expert community forum convened by Precision Medicine Group bringing scientists, physicians, regulators, commercial leaders, clients, and global experts together to address pressing challenges in biopharma innovation, including antibody drug conjugates and other advanced therapy topics.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• PathAIcoreStrategic or Co-development Partner · 25 April 2025Strategic collaboration to advance AI-powered clinical trial services and biospecimen products. The partnership combines PathAI's AI-powered pathology capabilities with Precision's clinical trial services and biospecimen offerings to enhance diagnostic development and clinical trial outcomes.
• SOPHiA GENETICScoreTechnology or Integration · 8 April 2025Partnership to expand biopharma services with the SOPHiA DDM Platform and its liquid biopsy capabilities. The collaboration integrates SOPHiA GENETICS' data analytics and liquid biopsy technology with Precision's service offerings to enhance biopharma客户的分子诊断和生物标志物开发能力。

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• IQVIA: Largest global CRO and life sciences data/technology company; overlaps directly with Precision for Medicine on clinical research services and with Precision AQ on commercial/HEOR capabilities, but at materially larger scale.
• ICON plc: Top-3 global CRO following its acquisition of PRA Health Sciences; competes head-to-head with Precision for Medicine across Phase I–IV trials and provides commercial/real-world evidence services analogous to Precision AQ.
• Labcorp (incl. Covance Drug Development / Fortrea): Major clinical laboratory network (central labs, specialty labs, biospecimens) that directly overlaps with Precision for Medicine's specialty labs, central lab, and biospecimen offerings, and competes via Fortrea in CRO services.

Direct peers

• Syneos Health: Biopharma services organization offering both clinical development (CRO) and commercialization services — the same end-to-end structure as Precision Medicine Group's Precision for Medicine + Precision AQ model.
• Charles River Laboratories: Global CRO with strong cell and gene therapy manufacturing and research services, overlapping with Precision for Medicine's advanced-therapy positioning and with Project Farma in CMC/manufacturing support.
• Medpace Holdings: Mid-to-large global CRO focused on clinical development for biotech and specialty pharma; directly comparable to Precision for Medicine's core CRO business with a similar mid-tier, science-led positioning.
• Parexel International: Privately-held global CRO (sponsors EQT and GIC) with biopharma clinical and commercialization services; overlaps with both halves of Precision Medicine Group's two-group structure.
• Worldwide Clinical Trials: Mid-sized global CRO focused on complex therapeutic areas; directly comparable to Precision for Medicine on clinical research scale and scientific depth.

Emerging players

• Veristat: Smaller, science-driven CRO specializing in oncology, rare disease, and advanced therapies; narrower overlap with Precision for Medicine's advanced-therapy and biomarker trial work.
• BioAgilytix Labs: Specialty bioanalytical and biomarker laboratory supporting clinical trials; directly comparable to Precision for Medicine's specialty labs and biomarker-driven research services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Precision4Med
• LinkedInlinkedin.com/company/home

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries17 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precision Medicine Group